New Regenerative Therapy Introduced at Dr. Kamakshi Memorial Hospitals
On September 10, 2026, Dr. Kamakshi Memorial Hospitals in Chennai, Tamil Nadu announced the clinical launch of a DCGI‑approved allogeneic bone‑marrow‑derived mesenchymal stem cell (MSC) therapy for knee osteoarthritis (OA). The therapy, developed by Stempeutics Research and made commercially available by Cipla, is positioned as an intermediate treatment option for patients with Grade II and Grade III knee OA, aiming to reduce inflammation, modulate immune response, and protect cartilage, thereby preserving the natural knee and potentially delaying or avoiding total knee replacement.
Orthopedic specialists Dr. Deepak Kumar K S, Chief Consultant – Orthopedic Surgeon, Knee Replacement and Mako Stryker Expert, and Dr. Sathish Kumar Thangamani, Senior Assistant Professor at Stanley Medical College and consultant at the hospital, jointly oversee patient selection and administration. Both physicians emphasize a “knee‑preservation‑first” philosophy, stating that surgery should not be the default pathway and that emerging regenerative options should be considered when clinically appropriate.
The therapy’s regulatory status is highlighted: it has received explicit approval from the Drugs Controller General of India (DCGI), marking the first instance of a regulated stem‑cell product being offered in clinical practice within Tamil Nadu. The press release notes that the treatment is intended for carefully selected patients after thorough clinical assessment, with decisions based on disease severity and individual health status.
For further information, the hospital directs readers to its website (www.drkmh.com). The release concludes with a disclaimer that the content is provided under an arrangement with Newsvoir and that PTI assumes no editorial responsibility.